A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).

A Phase 3 Randomized, Double-Blind Study Assessing the Efficacy and Safety of PF-06410293 and Adalimumab in Combination With Methotrexate in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate

Category & Conditions:
Immune System Diseases and Conditions
Medicine:
PF-06410293
ClinicalTrials.gov Identifier (NCT):
Protocol ID:
B5381002
Open Plain Language Summary Result:Click here